BioStock: Italian distributor expresses confidence in Chordate Medical's migraine treatment

Report this content

Italy is Chordate Medical’s most active market to date, in large part due to the distributor Vedise Hospital that has performed solid work regarding sales of K.O.S for the treatment of rhinitis. Now that Chordate has received CE marking in chronic migraine, K.O.S. will be launched as a migraine treatment in Italy. In an interview with BioStock, Vedise Hospital expresses high hopes for this launch and talks about its plans in connection with the launch.

Read the full article at biostock.se: 

https://www.biostock.se/en/italian-distributor-expresses-confidence-in-chordate-medicals-migraine-treatment/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Subscribe

Documents & Links

Quick facts

BioStock: Italian distributor expresses confidence in Chordate Medical's migraine treatment
Tweet this